This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Top Ranked Momentum Stocks to Buy for May 28th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, May 28th.
5 Health Care Stocks to Bet on as Coronavirus Woes Linger
by Sreoshi Bera
The health care industry has been rallying so far this year on constant testing and COVID-19 vaccine trials.
NuCana (NCNA) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
We expect NuCana (NCNA) to provide updates on its pipeline when it releases fourth-quarter results.
Innate Pharma's Filing for Leukemia Drug Accepted in Europe
by Zacks Equity Research
The EMA accepts Innate's (IPHA) marketing application for Lumoxiti, developed to treat relapsed/refractory hairy cell leukemia in adult patients having received minimum two prior systemic therapies.
New Strong Buy Stocks for December 11th
by Tirthankar Chakraborty
Here are 4 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
Sorrento Turns Down Two All-Cash Takeover Bids, Stock Jumps
by Zacks Equity Research
Sorrento (SRNE) rejects an all-cash unsolicited acquisition proposal from two unknown biopharmaceutical companies. The stock shoots up.
Achillion's (ACHN) Danicopan Gets EMA's PRIME Tag for PNH
by Zacks Equity Research
Achillion's (ACHN) lead pipeline candidate danicopan receives PRIME status from the EMA as a treatment option for PNH in patients, who are not adequately responding to a C5 inhibitor.
Lilly's Pancreatic Cancer Candidate Fails in Phase III Study
by Zacks Equity Research
Lilly's (LLY) immunotherapy candidate, pegilodecakin, falls short of meeting the primary endpoint of OS benefit in a phase III study investigating its usage in metastatic pancreatic cancer.
Novavax Begins Phase III Study on Influenza Vaccine Candidate
by Zacks Equity Research
Novavax (NVAX) starts a pivotal late-stage study on its pipeline candidate NanoFlu influenza vaccine in senior patients. Shares up.
Seattle Genetics' Enfortumab Vedotin BLA Gets Priority Review
by Zacks Equity Research
The FDA accepts Seattle Genetics (SGEN) and Astellas' BLA for enfortumab vedotin under a priority review to treat advanced/metastatic urothelial cancer. A verdict is pending on Mar 15, 2020.
Amgen's Kyprolis Combo Improves PFS in Multiple Myeloma Study
by Zacks Equity Research
Amgen's (AMGN) phase III study on Kyprolis in combination with dexamethasone and J&J's Darzalex meets the goal of progression-free survival for treating relapsed or refractory multiple myeloma.
FDA Grants Orphan Drug Status to Acceleron's PAH Candidate
by Zacks Equity Research
The FDA assigns an orphan drug status to Acceleron's (XLRN) investigational therapy sotatercept for the treatment of patients with pulmonary arterial hypertension. Shares inch up.
NuCana plc (NCNA) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in NuCana plc (NCNA).
Acorda (ACOR) Down More Than 60% in 3 Months: Here's Why
by Zacks Equity Research
Acorda's (ACOR) lead MS drug Ampyra is hit by generic rivalry in the United States, which is hurting the company's top line. Parkinson's disease drug Inbrija can be an ideal replacement.
Akari's Nomacopan Gets Orphan Drug Tag for Rare Disease
by Zacks Equity Research
The FDA assigns an orphan drug status to Akari's (AKTX) nomacopan for the treatment of hematopoietic stem cell transplantation-associated thrombotic microangiopathy, which is a rare disease.
NuCana Stops Patient Enrollment in Pancreatic Cancer Study
by Zacks Equity Research
NuCana (NCNA) suspends patient enrollment in the phase III study on Acelarin, currently evaluated for treating patients with metastatic pancreatic cancer, who were unfit for combination chemotherapy.
NuCana Initiates Dosing in Phase I Study for Solid Tumors
by Zacks Equity Research
NuCana (NCNA) doses the first patient in a phase I study on NUC-7738, which is being evaluated for the treatment of advanced solid tumors.
NuCana's Biliary Tract Cancer Candidate Gets Orphan Drug Tag
by Zacks Equity Research
The FDA confers an orphan drug designation on NuCana's (NCNA) pipeline candidate, Acelarin, for treating patients with biliary tract cancer
Will NuCana Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in NuCana.
Amarin Down on Lower '19 View, Posts Preliminary '18 Results
by Zacks Equity Research
Amarin (AMRN) reports preliminary results for 2018 and issues guidance for 2019. While the results exceeded estimates, outlook missed the same.
Four Biotech Stocks That Popped More Than 50% in 2018
by Zacks Equity Research
The biotech sector has failed to impress the investors in 2018 which has underperformed the broader S&P 500 market. However, we provide four biotech companies which performed well in this scenario.
NuCana Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
NuCana PLC has been struggling lately, but the selling pressure may be coming to an end soon.